If you already own the professor, you can have her “prove” HCQ and IVM don’t work, and include her on the NIH COVID guidelines committee to kill those drugs and push remdesivir

The damage done, she rotated off the NIH COVID guidelines committee. Interesting how many HIV docs/ Fauci acolytes were on the committee.

Dr. Susanna Naggie

https://medschool.duke.edu/profile/susanna-naggie

Member of the NIH COVID treatment Guidelines Committee

Recommendation

• The Panel recommends against the use of ivermectin for the treatment of COVID-19

• Other Agents That Have Been Studied or Are Under Investigation
  • The Panel recommends against the use of chloroquine or hydroxychloroquine with or without
  azithromycin (AIIa), lopinavir/ritonavir, and other HIV protease inhibitors (AIII) for the
  outpatient treatment of COVID-19.
  • The Panel recommends against the use of antibacterial therapy (e.g., azithromycin, doxycycline) for the outpatient treatment of COVID-19 in the absence of another indication (AIII).
  • Other agents have undergone or are currently undergoing investigation in the outpatient setting. Although none of these are currently recommended, additional information can be found in sections of the guidelines that address:
  • Drugs such as colchicine, fluvoxamine, ivermectin, inhaled corticosteroids, and metformin
  • Supplements such as vitamin C, vitamin D, and zinc
  • The Panel recommends against the use of anticoagulants and antiplatelet therapy for the prevention of venous thromboembolism or arterial thrombosis unless the patient has other indications for the therapy or is participating in a clinical trial (AIIa). For more information, see Antithrombotic Therapy in Patients With COVID-19.

Professor of Medicine, Vice Dean for Clinical Research, Member in the Duke Clinical Research Institute

Dr. Susanna Naggie completed her medical education at Johns Hopkins School of Medicine and her internal medicine training at Duke University Medical Center (DUMC), where she also served as a Chief Resident in Internal Medicine.  She completed her Infectious Diseases (ID) fellowship training at Duke and then joined the faculty in the Division of ID. She is a Professor of Medicine and currently holds joint appointments at the Duke Clinical Research Institute and at the Durham Veterans Affairs Medical Center (DVAMC). Dr. Naggie has dedicated her academic career to the care of patients with HIV and viral hepatitis, with a research program focused on understanding the mechanisms of accelerated liver fibrogenesis in this population and discovery of biomarkers for risk-stratification in this patient population. In addition to her investigator-initiated research program, Dr. Naggie is also involved in multiple clinical trials and clinical registries with a particular focus on HIV and liver disease and emerging infections including COVID-19. She is a member of the DHHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV and the CDC/NIH/IDSA-HIVMA Opportunistic Infections Guideline Committee and is a prior member of the AASLD-IDSA HCV Treatment and Management Guidelines and the NIH COVID-19 Treatment Guidelines. She serves as a Deputy Editor for Clinical Infectious Diseases. Dr. Naggie currently serves as the Vice Dean for Clinical Research, Co-Director for the Duke Center for AIDS Research and the interim director for the Duke Clinical and Translational Sciences Institute.  

Grants

• A randomized controlled trial of a novel, evidence-based algorithm for managing lower respiratory tract infection in a resource-limited setting awarded by National Institutes of Health 2022 – 2027

• Duke Training Grant in Digestive Diseases and Nutrition awarded by National Institutes of Health 1988 – 2027

• Prediction and Prevention of Hepatic Decompensation in Patients with Cirrhosis awarded by National Institutes of Health 2021 – 2026

• Interdisciplinary Research Training Program in AIDS awarded by National Institutes of Health 2010 – 2025

• VTEU 14-0053 Task C Option 2 Protocol Implementation awarded by National Institutes of Health 2018 – 2024

• TDE Pickett Road Infrastructure awarded by Duke Endowment 2021 – 2024

• Unified Program for Therapeutics in Children awarded by National Institutes of Health 2019 – 2024

• VTEU: Task Area D: Research Laboratory Analysis Protocol #14-0053 awarded by National Institutes of Health 2015 – 2024

• Spatial transcriptomic profiling to assess liver fibrosis pathways associated with HIV infection awarded by St. Louis University 2023 – 2024

• Ancillary Studies of NAFLD and NASH in HIV infected Adults awarded by The Trustees of Indiana University 2022 – 2023

Publications—each sinks the drug

• Naggie, Susanna, Aaron Milstone, Mario Castro, Sean P. Collins, Seetha Lakshmi, Deverick J. Anderson, Lizbeth Cahuayme-Zuniga, et al. “Hydroxychloroquine for pre-exposure prophylaxis of COVID-19 in health care workers: a randomized, multicenter, placebo-controlled trial Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine (HERO-HCQ).” In Int J Infect Dis, 129:40–48, 2023. https://doi.org/10.1016/j.ijid.2023.01.019.

• Naggie, Susanna, David R. Boulware, Christopher J. Lindsell, Thomas G. Stewart, Alex J. Slandzicki, Stephen C. Lim, Jonathan Cohen, et al. “Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19: A Randomized Clinical Trial.” Jama 329, no. 11 (March 21, 2023): 888–97. https://doi.org/10.1001/jama.2023.1650.

Below are the (ridiculous) NIH Treatment Guidelines for COVID in hospitalized and non-hospitalized patients

https://www.covid19treatmentguidelines.nih.gov/tables/management-of-hospitalized-adults-summary/

https://www.covid19treatmentguidelines.nih.gov/tables/management-of-nonhospitalized-adults-summary/